Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adefovir dipivoxil.

S Noble1, K L Goa

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Adefovir dipivoxil effectively reduced HIV viral load in patients on standard therapy. The drug demonstrated sustained viral suppression and was particularly effective in individuals with specific resistance mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Adefovir dipivoxil is an ester prodrug of adefovir (PMEA), an acyclic nucleoside phosphonate reverse transcriptase inhibitor.
  • It offers improved oral bioavailability compared to its parent compound.

Purpose of the Study:

  • To evaluate the efficacy and safety of adefovir dipivoxil in HIV-infected patients.
  • To assess viral load reduction and maintenance of viral suppression with adefovir dipivoxil treatment.

Main Methods:

  • A 6-month double-blind, placebo-controlled study involving HIV patients receiving standard antiretroviral therapy.
  • A virological substudy analyzed drug effectiveness based on baseline viral resistance mutations.
  • A subsequent 6-month nonblind extension phase monitored sustained viral suppression.

Related Experiment Videos

Main Results:

  • Adefovir dipivoxil (120mg daily) significantly reduced viral load compared to placebo.
  • The drug was most effective in patients with baseline M184V lamivudine resistance mutations.
  • Viral suppression was maintained for up to 12 months, even with the emergence of new reverse transcriptase mutations.

Conclusions:

  • Adefovir dipivoxil is an effective agent for reducing viral load in HIV patients.
  • Sustained viral suppression can be achieved with adefovir dipivoxil, with notable efficacy in specific resistance mutation profiles.
  • Key adverse events include gastrointestinal disturbances, hepatic effects, and renal abnormalities; L-carnitine coadministration is recommended for potential carnitine level reductions.